Cytel: model-informed drug development expanding area of focus
Cecilia Fosser, Director Quantitative Pharmacology and Pharmacometrics at Cytel, told us the group is organized into four areas: Pharmacometric Services, Quantitative pharmacology, Comparator Database Creation, and Phase 1 Biometric services.
By bringing together a skilled team focused on these services, Fosser told us the company will develop “further efficiencies, and deliver high-quality solutions” to help its customers “gain deeper knowledge of their drug candidates’ properties, enabling a clear understanding of the associated benefit-risk ratio.”
Model informed drug development
Model-informed drug development is an expanding area of focus within the clinical development services and software provider’s biopharma client portfolio, Fosser said.
Consequently, the company expects to continue growing the team to meet customer demand.
“In addition to technical skills, we look for people who demonstrate a passion for exploring data, innovating new solutions and are able to collaborate closely with our customers,” added Fosser.
The new organization is also working to streamline its services “in the growing space of model informed drug development and decision making,” she said, adding that there are myriad possible analyses and decision-guiding tools.
“For example, model- based meta-analysis is an increasingly utilized strategy to help biopharma sponsors conduct competitive benchmarking, generate target values for decision-making and assess comparative effectiveness,” Fosser explained.
“By applying our combined software development, biostatistics and pharmacometrics know-how we can efficiently provide answers to help answer critical research questions from early development through to post registration.”
